Martin Roessner

Martin brings over 40 years of experience in biostatistics for Phase I-IV drug development from his 34-year tenure overseeing product submissions at Sanofi- Aventis (and its predecessor companies). Since 2010, he has led Parexel’s global biostatistics services, supporting the planning and execution for all drug and device development phases, including regulatory meetings and submissions. Martin has supported numerous successful product marketing applications, negotiated labeling changes, and managed interactions with many of the world’s foremost health authorities. He received an M.S. in mathematics and biostatistics from RWTH Aachen University.